<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04916327</url>
  </required_header>
  <id_info>
    <org_study_id>HM20020955-1</org_study_id>
    <nct_id>NCT04916327</nct_id>
  </id_info>
  <brief_title>Examining the Impact of Exercise Training on Vascular Dysfunction in Individuals With Mental Health Disorders - Study 1</brief_title>
  <official_title>Examining the Impact of Exercise Training on Vascular Dysfunction in Individuals With Mental Health Disorders - Study 1</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virginia Commonwealth University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Virginia Commonwealth University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to examine the role oxidants, substances produced in&#xD;
      the blood that can damage blood vessel function, may play in blood vessel function in healthy&#xD;
      individuals as well as individuals with mental health disorders (posttraumatic stress&#xD;
      disorder (PTSD) and/or generalized anxiety disorder (GAD)).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study #1 is made up of three sessions done on three separate days and the entire study can be&#xD;
      completed in as little as two weeks. All testing sessions will take place at the Exercise&#xD;
      Physiology Research Laboratory. Volunteers will be asked to participate in one initial&#xD;
      testing session (Visit 1) lasting &lt; 1 hour that will help make them more familiar with the&#xD;
      study equipment and procedures, determine body measures (height, weight, body fat), determine&#xD;
      the maximum strength of their forearm and calf, and require one blood draw. The following two&#xD;
      testing sessions (Visits 2 and 3) with each session lasting between 2-3 hours that will&#xD;
      involve multiple tests designed to determine the health of their blood vessels. For Visit #2&#xD;
      they will be randomly given either antioxidant pills or placebo pills to determine the effect&#xD;
      of oxidants on blood vessel health. For Visit #3, they will be given whatever set of pills&#xD;
      (antioxidant or placebo) that they did not receive during Visit #2.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 23, 2021</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Arm Vascular Function at Rest (Flow Mediated Dilation Test)</measure>
    <time_frame>Baseline to the end of the final visit, about 2 weeks</time_frame>
    <description>Change in Brachial Artery Dilation from Baseline Values</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Leg Vascular Function (Passive Leg Movement Test)</measure>
    <time_frame>Baseline to the end of the final visit, about 2 weeks</time_frame>
    <description>Change in Leg Blood Flow Values from Baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Arm Vascular Function in Response to Exercise (Handgrip Exercise Test)</measure>
    <time_frame>Baseline to the end of the final visit, about 2 weeks</time_frame>
    <description>Change in Brachial Artery Dilation from Baseline Values</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">720</enrollment>
  <condition>Peripheral Vascular Diseases</condition>
  <arm_group>
    <arm_group_label>Antioxidant then Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will ingest an antioxidant cocktail prior to their second visit and a placebo prior to third second visit</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo then Antioxidant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will ingest a placebo prior to their second visit and an antioxidant cocktail prior to their third visit.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Antioxidant</intervention_name>
    <description>Subjects will ingest an antioxidant cocktail containing 800 milligrams of alpha lipoic acid, 1 gram of vitamin C (ascorbic acid), and 400 milligrams of vitamin E (alpha tocopherol).</description>
    <arm_group_label>Antioxidant then Placebo</arm_group_label>
    <arm_group_label>Placebo then Antioxidant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects will ingest placebo (microcrystalline cellulose) pills.</description>
    <arm_group_label>Antioxidant then Placebo</arm_group_label>
    <arm_group_label>Placebo then Antioxidant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  apparently healthy and free of overt cardiovascular, pulmonary, or metabolic disease&#xD;
&#xD;
          -  for PTSD group, a score of ≥ 33 on PCL-5 checklist&#xD;
&#xD;
          -  for GAD group, a score of ≥ 10 on the GAD-7 self-report scale and &lt; 33 on the PCL-5&#xD;
             checklist&#xD;
&#xD;
          -  for Healthy Control group, a score of ≤ 10 on the GAD-7 self-report scale and &lt; 33 on&#xD;
             the PCL-5 checklist&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  taking medications that could influence cardiovascular function&#xD;
&#xD;
          -  current smokers who have recently quit smoking&#xD;
&#xD;
          -  illicit drug use or excessive alcohol consumption&#xD;
&#xD;
          -  pregnant women&#xD;
&#xD;
          -  significant calorie restriction or vitamin/mineral deficiencies&#xD;
&#xD;
          -  limited English proficiency&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ryan Garten, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Virginia Commonwealth University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ryan Garten, PhD</last_name>
    <phone>(804) 828-1948</phone>
    <email>rsgarten@vcu.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>May 24, 2021</study_first_submitted>
  <study_first_submitted_qc>June 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 7, 2021</study_first_posted>
  <last_update_submitted>August 24, 2021</last_update_submitted>
  <last_update_submitted_qc>August 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cardiovascular disease</keyword>
  <keyword>vascular function</keyword>
  <keyword>PTSD</keyword>
  <keyword>GAD</keyword>
  <keyword>Oxidant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antioxidants</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

